{"id":56683,"date":"2026-02-09T21:26:52","date_gmt":"2026-02-09T13:26:52","guid":{"rendered":"https:\/\/flcube.com\/?p=56683"},"modified":"2026-02-09T21:26:53","modified_gmt":"2026-02-09T13:26:53","slug":"gileads-kite-pharma-secures-fda-label-expansion-for-yescarta-in-primary-cns-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56683","title":{"rendered":"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma"},"content":{"rendered":"\n<p><strong>Kite Pharma<\/strong>, a <strong>Gilead Sciences (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>)<\/strong> subsidiary, announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has <strong>approved updates to Yescarta&#8217;s prescribing information<\/strong>, <strong>removing usage restrictions<\/strong> for patients with <strong>relapsed or refractory (R\/R) primary central nervous system lymphoma (PCNSL)<\/strong>. The label modification reflects <strong>expanded safety data<\/strong> supporting CAR\u2011T therapy use in this challenging CNS malignancy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Kite Pharma (Gilead Sciences subsidiary, NASDAQ: GILD)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Yescarta (axicabtagene ciloleucel) \u2013 CD19\u2011directed CAR\u2011T therapy<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Prescribing information update (label expansion)<\/td><\/tr><tr><td><strong>Modification<\/strong><\/td><td>Removal of usage restrictions for R\/R PCNSL patients<\/td><\/tr><tr><td><strong>Basis<\/strong><\/td><td>Robust safety data in eligible PCNSL population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approved-indication-portfolio\">Approved Indication Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Patient Population<\/th><th>Approval Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Large B\u2011cell lymphoma (LBCL)<\/strong><\/td><td>Refractory to first\u2011line immunochemotherapy or relapse within 12 months<\/td><td>Approved<\/td><\/tr><tr><td><strong>Relapsed\/refractory LBCL<\/strong><\/td><td>After two or more lines of systemic therapy<\/td><td>Approved<\/td><\/tr><tr><td><strong>Relapsed\/refractory follicular lymphoma (FL)<\/strong><\/td><td>After two or more lines of systemic therapy<\/td><td>Approved<\/td><\/tr><tr><td><strong>Primary CNS lymphoma (PCNSL)<\/strong><\/td><td>Relapsed or refractory; usage restrictions <strong>now removed<\/strong><\/td><td><strong>Label updated<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-therapeutic-mechanism\">Technology Profile &amp; Therapeutic Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> <strong>Genetically modified autologous CD19\u2011directed CAR\u2011T cell immunotherapy<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li>Patient&#8217;s own T\u2011cells are <strong>genetically engineered<\/strong> to express <strong>anti\u2011CD19 chimeric antigen receptor<\/strong><\/li>\n\n\n\n<li>Expanded ex\u2011vivo and <strong>reinfused<\/strong> to target and eliminate CD19\u2011positive B\u2011cell malignancies<\/li>\n\n\n\n<li><strong>Single\u2011infusion curative potential<\/strong> vs. chronic chemotherapy or stem cell transplant<\/li>\n\n\n\n<li><strong>CNS Penetration:<\/strong> Yescarta demonstrates <strong>blood\u2011brain barrier crossing capability<\/strong>, enabling efficacy in <strong>primary CNS lymphoma<\/strong> where tumor is confined to brain\/spinal cord<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-impact\">Strategic Positioning &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PCNSL Unmet Need:<\/strong> Primary CNS lymphoma represents <strong>3-5% of all brain tumors<\/strong> with <strong>poor prognosis<\/strong>; standard high\u2011dose methotrexate achieves limited durability, and <strong>CAR\u2011T offers potential curative option<\/strong> for R\/R patients.<\/li>\n\n\n\n<li><strong>Label Flexibility Value:<\/strong> <strong>Removal of usage restrictions<\/strong> (vs. specific indication approval) enables <strong>broader physician discretion<\/strong> and <strong>payer coverage flexibility<\/strong>, accelerating commercial uptake without requiring new randomized trials.<\/li>\n\n\n\n<li><strong>Yescarta Franchise Defense:<\/strong> Label expansion <strong>protects market position<\/strong> against <strong>Bristol Myers Squibb&#8217;s Breyanzi<\/strong> and <strong>Novartis&#8217;s Kymriah<\/strong>, which are pursuing CNS lymphoma indications; reinforces <strong>Kite&#8217;s first\u2011mover advantage<\/strong> in aggressive B\u2011cell malignancies.<\/li>\n\n\n\n<li><strong>Gilead Cell Therapy Growth:<\/strong> PCNSL expansion supports Gilead&#8217;s <strong>$3+ billion CAR\u2011T revenue target<\/strong>, diversifying beyond LBCL into <strong>orphan CNS indications<\/strong> with premium pricing potential.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-outlook\">Clinical &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Execution Plan<\/th><\/tr><\/thead><tbody><tr><td><strong>Commercial Launch<\/strong><\/td><td>Immediate promotion to neuro\u2011oncology and lymphoma specialists<\/td><\/tr><tr><td><strong>Payer Engagement<\/strong><\/td><td>Secure coverage for PCNSL under existing LBCL CAR\u2011T policies<\/td><\/tr><tr><td><strong>Real\u2011World Evidence<\/strong><\/td><td>Publish expanded PCNSL safety\/efficacy data to support guidelines<\/td><\/tr><tr><td><strong>Pipeline Synergy<\/strong><\/td><td>Explore Yescarta combinations with BTK inhibitors in CNS lymphoma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Yescarta commercial performance in PCNSL, CAR\u2011T market share dynamics, and Gilead Sciences&#8217; cell therapy revenue growth. Actual results may differ due to competitive responses from BMS and Novartis, reimbursement variability for CNS indications, and long\u2011term safety monitoring requirements for CAR\u2011T neurotoxicity.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,21,77,226,1568,1025],"class_list":["post-56683","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-car-t","tag-cell-therapy","tag-gilead-sciences","tag-kite-pharma","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug Administration (FDA) has approved updates to Yescarta&#039;s prescribing information, removing usage restrictions for patients with relapsed or refractory (R\/R) primary central nervous system lymphoma (PCNSL). The label modification reflects expanded safety data supporting CAR\u2011T therapy use in this challenging CNS malignancy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56683\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug Administration (FDA) has approved updates to Yescarta&#039;s prescribing information, removing usage restrictions for patients with relapsed or refractory (R\/R) primary central nervous system lymphoma (PCNSL). The label modification reflects expanded safety data supporting CAR\u2011T therapy use in this challenging CNS malignancy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56683\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T13:26:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T13:26:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56683#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56683\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma\",\"datePublished\":\"2026-02-09T13:26:52+00:00\",\"dateModified\":\"2026-02-09T13:26:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56683\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Gilead Sciences\",\"Kite Pharma\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56683#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56683\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56683\",\"name\":\"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-09T13:26:52+00:00\",\"dateModified\":\"2026-02-09T13:26:53+00:00\",\"description\":\"Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug Administration (FDA) has approved updates to Yescarta's prescribing information, removing usage restrictions for patients with relapsed or refractory (R\\\/R) primary central nervous system lymphoma (PCNSL). The label modification reflects expanded safety data supporting CAR\u2011T therapy use in this challenging CNS malignancy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56683#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56683\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56683#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma - Insight, China&#039;s Pharmaceutical Industry","description":"Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug Administration (FDA) has approved updates to Yescarta's prescribing information, removing usage restrictions for patients with relapsed or refractory (R\/R) primary central nervous system lymphoma (PCNSL). The label modification reflects expanded safety data supporting CAR\u2011T therapy use in this challenging CNS malignancy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56683","og_locale":"en_US","og_type":"article","og_title":"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma","og_description":"Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug Administration (FDA) has approved updates to Yescarta's prescribing information, removing usage restrictions for patients with relapsed or refractory (R\/R) primary central nervous system lymphoma (PCNSL). The label modification reflects expanded safety data supporting CAR\u2011T therapy use in this challenging CNS malignancy.","og_url":"https:\/\/flcube.com\/?p=56683","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T13:26:52+00:00","article_modified_time":"2026-02-09T13:26:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56683#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56683"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma","datePublished":"2026-02-09T13:26:52+00:00","dateModified":"2026-02-09T13:26:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56683"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CAR-T","Cell-therapy","Gilead Sciences","Kite Pharma","NASDAQ: GILD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56683#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56683","url":"https:\/\/flcube.com\/?p=56683","name":"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-09T13:26:52+00:00","dateModified":"2026-02-09T13:26:53+00:00","description":"Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug Administration (FDA) has approved updates to Yescarta's prescribing information, removing usage restrictions for patients with relapsed or refractory (R\/R) primary central nervous system lymphoma (PCNSL). The label modification reflects expanded safety data supporting CAR\u2011T therapy use in this challenging CNS malignancy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56683#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56683"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56683#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead\u2019s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56683"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56683\/revisions"}],"predecessor-version":[{"id":56684,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56683\/revisions\/56684"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}